General MedicationsIV (INFUSION)Standard
ONTRUZANT
TRASTUZUMAB-DTTB
Standard Dose
420MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ONTRUZANT is listed in Drugs@FDA under application 761100 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TRASTUZUMAB-DTTB Form and strength POWDER;IV (INFUSION) - 420MG Sponsor SAMSUNG BIOEPIS CO LTD Submission history Latest submission status date: 2025-12-05 00:00:00.
Structured Monograph
Clinical summary
Approval overview ONTRUZANT is listed in Drugs@FDA under application 761100 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient TRASTUZUMAB-DTTB Form and strength POWDER;IV (INFUSION) - 420MG Sponsor SAMSUNG BIOEPIS CO LTD Submission history Latest submission status date: 2025-12-05 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.